Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms.

The Journal of antimicrobial chemotherapy - 1 Nov 2007

Levin Mark-David, den Hollander Jan G, van der Holt Bronno, Rijnders Bart J, van Vliet Martin, Sonneveld Pieter, van Schaik Ron H N

Abstract excerpt

OBJECTIVES: Voriconazole, like all other antifungals of the azole group, is potentially hepatotoxic. A large interpatient variability of liver enzyme elevations during oral or intravenous (iv) voriconazole administration is observed. This interpatient variability may be explained by differences in voriconazole metabolism because of cytochrome P450 polymorphisms. We examined the relationship between cytochrome...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Antifungal Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemical and Drug Induced Liver Injury

Share to Cytochrome P-450 Enzyme System

Share to Injections, Intravenous

Share to Pyrimidines

Share to Triazoles

Share to Voriconazole

Source

Identifiers

PMID: 17827141
DOI: 10.1093/jac/dkm330

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms.PMID 17827141Read ↗

Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients.Semantic proximity Read ↗

<i><scp>CYP</scp>2C19</i> Polymorphisms and Therapeutic Drug Monitoring of Voriconazole: Are We Ready for Clinical Implementation of Pharmacogenomics?Semantic proximity Read ↗

Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis.Semantic proximity Read ↗

Impact of CYP2C19 genotype on voriconazole exposure and effect of voriconazole on the activity of CYP3A in patients with haematological malignancies.Semantic proximity Read ↗

Therapeutic drug monitoring of voriconazole.Semantic proximity Read ↗

The influence of CYP2C19 polymorphisms on voriconazole trough concentrations: Systematic review and meta-analysis.Semantic proximity Read ↗

CYP2C19-Guided Voriconazole Therapy: A Precision Medicine Approach to Mitigate Adverse Effects in Japanese Patients.Semantic proximity Read ↗

Influence of CYP2C19 Genotypes on the Occurrence of Adverse Drug Reactions of Voriconazole among Hematological Patients after Allo-HSCT.Semantic proximity Read ↗

Effect of Therapeutic Drug Monitoring and Cytochrome P450 2C19 Genotyping on Clinical Outcomes of Voriconazole: A Systematic Review.Semantic proximity Read ↗

Inflammation-driven variability in drug metabolism: Insights from voriconazole treatment of HSCT recipients.Semantic proximity Read ↗

Impact of cytochrome P450 2C19 polymorphisms on the clinical efficacy and safety of voriconazole: an update systematic review and meta-analysis.Semantic proximity Read ↗

Genetic and clinical predictors of voriconazole pharmacokinetics and hepatotoxicity: focused on CYP2C19 normal and intermediate metabolizers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.